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Objective. Dysregulation of innate and adaptive immune responses contributes to the pathogenesis of systemic lupus erythematosus (SLE) and its associated premature vascular damage. No drug to date targets both systemic inflammatory disease and the cardiovascular complications of SLE. Tofacitinib is a JAK inhibitor that blocks signaling downstream of multiple cytokines implicated in lupus pathogenesis. While clinical trials have shown that tofacitinib exhibits significant clinical efficacy in various autoimmune diseases, its role in SLE and the associated vascular pathology remains to be characterized.
Methods. MRL/lpr lupus-prone mice were administered tofacitinib or vehicle by gavage for 6 weeks (therapeutic arm) or 8 weeks (preventive arm). Nephritis, skin inflammation, serum levels of autoantibodies and cytokines, mononuclear cell phenotype and gene expression, neutrophil extracellular traps (NETs) release, endothelium-dependent vasorelaxation, and endothelial differentiation were compared in treated and untreated mice.
Results. Treatment with tofacitinib led to significant improvement in measures of disease activity, including nephritis, skin inflammation, and autoantibody production. In addition, tofacitinib treatment reduced serum levels of proinflammatory cytokines and interferon responses in splenocytes and kidney tissue. Tofacitinib also modulated the formation of NETs and significantly increased endothelium-dependent vasorelaxation and endothelial differentiation. The drug was effective in both preventive and therapeutic strategies.
Conclusion. Tofacitinib modulates the innate and adaptive immune responses, ameliorates murine lupus, and improves vascular function. These results indicate that JAK inhibitors have the potential to be beneficial in SLE and its associated vascular damage.
Systemic lupus erythematosus (SLE) is a chronic heterogeneous autoimmune syndrome that primarily afflicts young women, targeting many organs and tissues, especially the kidneys and skin. A key feature of SLE is the dysregulation of innate and adaptive immune responses, which is associated with loss of tolerance and the production of autoantibodies (1, 2) . T cells are considered to play major roles in SLE by amplifying autoimmune responses once tolerance is compromised. Indeed, lupus T cells display aberrant cytokine secretion and cell signaling properties and promote inappropriate recruitment and activation of B cells and dendritic cells at sites of inflammation (3) . A consistent finding in SLE is exaggerated production of interferon (IFN), which is thought to play key roles in disease pathogenesis (3) (4) (5) (6) .
Overproduction of type I IFNs may also play pivotal roles in the premature development of atherosclerosis observed in SLE (7) (8) (9) (10) . In addition, the interplay between type I IFNs and aberrant neutrophil function with enhanced capacity to form neutrophil extracellular traps (NETs) has recently been proposed as a key proinflammatory loop that can further propagate immune dysregulation and tissue damage (2) . Because of its complexity and clinical heterogeneity, treatment of SLE is challenging, and current therapies, while effective, are associated with significant complications. Importantly, no drug has thus far demonstrated efficacy in reducing cardiovascular risk in SLE.
The JAK/STAT pathway is the major signaling cascade downstream of type I and type II cytokine receptors. JAKs have been shown to be an effective therapeutic target for various autoimmune and inflammatory diseases driven by cytokines (11, 12) . Tofacitinib is a first-generation JAK inhibitor that inhibits JAK-1, JAK-3, and, to a lesser extent, JAK-2 (13, 14) . Since common g-chain-using cytokines use JAK-1 and JAK-3, the JAK inhibitor tofacitinib efficiently blocks their signaling cascades. Tofacitinib also blocks gp130-using cytokines as well as signaling downstream of type I/II IFNs. Tofacitinib may therefore have diverse effects on cytokines and cells that contribute to SLE pathogenesis, including subsets of CD41 T cells (helper T cells, including Th1 cells and pathogenic Th17 cells), CD81 T cells, B cells, and innate immune cells (15) (16) (17) . Although tofacitinib has been approved by regulatory agencies for the treatment of rheumatoid arthritis (RA) and is currently in clinical trials exploring its use in psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and ankylosing spondylitis, its effects in SLE have not been investigated (11) . Moreover, while some preliminary studies indicate that the JAK/STAT pathway can modulate vascular repair, the role of JAK inhibitors in SLE-associated vasculopathy is unknown (18, 19) .
The lupus mouse model MRL/MpJ-Fas lpr/lpr /J (MRL/lpr) recapitulates several of the clinical manifestations and immune dysregulation observed in human SLE. Indeed, these mice develop immune complex-mediated glomerulonephritis, inflammatory skin disease, aberrant T cell responses, dysregulated inflammatory cytokine synthesis, and an enhanced type I IFN signature (20) (21) (22) . MRL/lpr mice also represent a good model in which to study the vascular dysfunction and neutrophil dysregulation that are characteristic of lupus (23) . Therefore, this animal model was used to explore the effects of tofacitinib in preventing and treating murine lupus. We found that pharmacologic inhibition of the JAK/STAT pathway significantly ameliorated the lupus clinical phenotype and modulated the features of dysregulated innate and adaptive immunity that are characteristic of this disease.
Importantly, tofacitinib significantly improved vascular parameters, suggesting a potential modulatory role in cardiovascular risk in this disease.
MATERIALS AND METHODS

Mice and treatments.
Female MRL/lpr mice (#000485; The Jackson Laboratory) and haplotype-, age-, and sex-matched control MRL/MpJ mice (#000486; The Jackson Laboratory) were maintained under specific pathogen-free conditions and used in accordance with National Institutes of Health (NIH) guidelines under the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)-approved animal study protocol #A015-02-01. Tofacitinib (Pfizer) was suspended in 0.5% methylcellulose/0.025% Tween 20 (Sigma-Aldrich) for in vivo studies or in DMSO for in vitro use. MRL/lpr mice received daily administration of vehicle or tofacitinib (10 mg/kg) for 6 weeks (therapeutic treatment trial) or 8 weeks (preventive treatment trial) by oral gavage ( Figure 1A ). The numbers of animals used for experiments were calculated based on previous studies using preventive or therapeutic treatments in murine SLE (24, 25) . Overall, the number of mice ranged from 6 to 14 per group. The prophylactic treatment was repeated 3 times, and the therapeutic treatment was repeated twice.
Assessment of lupus nephritis and histopathologic features. Kidneys and dorsal skin samples were harvested after perfusion with phosphate buffered saline, fixed with 10% buffered formalin (Sigma), and sections were cut and stained with hematoxylin and eosin. Clinical scores for nephritis and skin inflammation were obtained in a blinded manner, without knowledge of the experimental group. Histologic analysis of pathologic features of the glomeruli included assessment of inflammation, proliferation, crescent formation, and necrosis. A minimum of 30 glomeruli from at least 10 mice per group were scored. For each glomerulus, a score of 1-5 was assigned (where 1 5 normal, 2 5 moderate, 3 5 severe, 4 5 severe with crescent formation, and 5 5 necrosis). Scores for each mouse were summed and averaged to yield the glomerulonephritis score for the individual mouse. A total score of glomeruli was calculated as the sum of the severity of hypercellularity of the glomeruli, the distribution of hypercellularity of the glomeruli, and the number of sclerotic glomeruli.
For assessment of skin pathology, a score of 0-3 was assigned (where 0 5 normal, 1 5 mild, 2 5 moderate, and 3 5 severe) for the epidermis and dermis, which were evaluated separately. The total clinical skin score was calculated as the sum of the scores for the epidermal and dermal inflammation.
For both kidney and skin histology samples, scores for each mouse were summed and averaged to achieve a clinical score for the individual mouse. Immune complex deposition in kidney sections was processed and quantified as previously described (23, 26) . Urinary albumin and creatinine concentrations were measured using a mouse albumin enzyme-linked immunosorbent assay (ELISA; Alpha Diagnostics) and a creatinine assay (R&D Systems), respectively. Urinary albumin-to-creatinine ratios were then calculated. Blood urea nitrogen (BUN) and blood creatinine levels were measured by the NIH hematology section.
Cell isolation and flow cytometry. Spleens were harvested and weighed, and splenocytes were isolated as previously described (26) . Total splenocyte numbers were counted using a Nexcelom automated cell counter. Lymphocyte populations were gated (100,000 cells of the lymphocyte populations) and counted by flow cytometry. The CD31 T cell population and B2201 B cell population were counted after exclusion of the natural killer cell population. All antibodies were from commercial sources as indicated below. Flow cytometry acquisition was done with a FACSCanto analyzer (BD Biosciences). Data analysis was performed using FlowJo software (Tree Star Inc.). Fluorescein isothiocyanate-conjugated T cell receptor b (TCRb), allophycocyanin (APC)-Cy7-conjugated CD3, V500-conjugated CD4, Alexa Fluor 700-conjugated CD8, phycoerythrin-Cy7-conjugated B220, PerCP-Cy5.5-conjugated CD19, and PerCP-Cy5.5-conjugated TCRb were obtained from BD Biosciences. APC-eFluor 780-conjugated CD11c was obtained from eBioscience.
Quantification of serum autoantibodies and cytokines. Serum antinuclear antibodies (ANAs) and anti-doublestranded DNA (anti-dsDNA) antibodies were quantified by ELISA following the manufacturer's instructions (Alpha Diagnostics). Serum cytokines were quantified with a BioPlex Pro mouse cytokine assay (Bio-Rad).
Assessment of IFN-stimulated genes (ISGs) and JAK/ STAT-related gene expression in total splenocytes and in kidneys. Following euthanasia, kidney tissues were harvested and immediately frozen in RNAlater stabilization solution (ThermoFisher Scientific). Total RNA was isolated from kidney tissues and splenocytes using a mirVana microRNA kit (Life Technologies) and quantified with an Agilent 2100 Bioanalyzer. For quantitative polymerase chain reaction, complementary DNA was synthesized using a TaqMan reverse transcription kit (Life Technologies), and analysis was performed with a CFX96 Real-Time detection system (Bio-Rad) using specific primers and probes (Life Technologies). The comparative threshold cycle and an internal control (18S ribosomal RNA) were used to normalize the expression of the target genes. RNA from MRL/MpJ mice was used as a control. The fold induction in gene expression was calculated by dividing the DDC t values in the vehicle-treated MRL/lpr mice by those in the MRL/MpJ mice or dividing the DDC t values in the tofacitinib-treated MRL/lpr mice by those in the MRL/MpJ mice. The following primers and probes were used: for ISG-15, Mm01705338_s1; for CXCL10, Mm00445235_m1; for Mx-1, Mm00487796_m1; for STAT-1, Mm00439531_m1; for STAT-2, Mm00490880_m1; and for IFN-induced protein with tetratricopeptide repeats (IFIT-1), Mm00515153_m1. Expression levels of 547 immune-related genes were analyzed using an nCounter Mouse Immunology code set (NanoString Technologies) following the manufacturer's protocols. Data were normalized based on internal reference genes provided by the manufacturer.
Quantification of NET release and endothelial cell differentiation and assessment of endothelium-dependent vasorelaxation. Mice were euthanized, and their tibias and femurs were collected. Bone marrow neutrophils were obtained as previously described and plated at a density of 0.25 3 10 6 cells/ cm 2 in RPMI 1640 without phenol red (23) . For the Sytox green assay (see below), cells were seeded on poly-L-lysine-coated coverslips for a 15-minute adherence step. Upon adhesion, neutrophils were left untreated or were treated for 5 hours with lipopolysaccharide (LPS, 500 ng/ml) (Sigma) and then fixed with 4% paraformaldehyde.
Fluorescence microscopy. Coverslips were stained with antimyeloperoxidase (1:500 dilution; Dako) and Hoechst 33342 (1:10,000 dilution) and then mounted with ProLong Gold antifade reagent (all from Life Technologies). Cells were analyzed by fluorescence microscopy using a Zeiss LSM780 confocal microscope. Images were taken using a 403 objective (4003 total magnification). The percentage of neutrophils forming NETs was determined using Adobe Photoshop CS6 software. Endothelial progenitor cells were cultured and stained as previously described (27) .
Sytox green uptake assay. Untreated or LPS-treated neutrophils were incubated for 5 hours with 0.2 mM Sytox green (Life Technologies), then fixed as described above. The resulting fluorescence from extracellular DNA (NETs) was quantified (excitation at 485 nm, emission at 520 nm) using a FluoStar Omega spectrophotometer (BMG Labtech).
Assessment of endothelium-dependent vasorelaxation. After euthanasia, thoracic aortas were excised, cleaned, and cut into 2-mm length rings. The endothelium was left intact, and aortic rings were mounted in a myograph system (Danish Myo Technology). Vessels were precontracted with potassium sorbate sphere containing 100 mM potassium chloride and then returned to potassium sorbate sphere. Cumulative concentrations of phenylephrine (10 29 210 26 M) were then added to the bath to establish a concentration-response curve. A phenylephrine concentration corresponding to 80% maximum was added, and contraction was allowed to reach a stable plateau. To examine endothelium-dependent relaxation, acetylcholine (10 29 210 26 M) was added cumulatively to the bath, and a curve was generated. Finally, a normal vascular smooth muscle response was confirmed by removing phenylephrine and acetylcholine.
Plasma lipid and lipoprotein analysis. Plasma obtained after euthanasia was separated by centrifugation at 3,000g for 10 minutes at 48C, and analyzed for total and free cholesterol levels using Cholesterol E and Free Cholesterol E kits (Wako Diagnostics). Cholesteryl ester was calculated for each sample by subtracting free cholesterol from total cholesterol. To calculate high-density lipoprotein (HDL) cholesterol levels, low-density lipoprotein (LDL) was precipitated using a Cholesterol HDL kit and the precipitating reagents (Stanbio Laboratory). Levels of total and free cholesterol were determined as for the total serum samples. LDL cholesterol levels were calculated by subtracting the amount of HDL cholesterol from the total serum cholesterol. Free cholesterol and cholesteryl esters were calculated in a similar manner.
Statistical analysis. To calculate statistical significance, a nonparametric Mann-Whitney U test was used, except where indicated otherwise. A value of P , 0.05 was considered statistically significant. For endothelium-dependent vasorelaxation, curves were first analyzed using an asymmetric (5-parameter) logistic equation, and the significance of each data point was determined by two-way analysis of variance. Except where indicated otherwise, results are reported as the mean 6 SEM.
RESULTS
Limited manifestations of lupus following preventive treatment with tofacitinib in MRL/lpr mice. MRL/ lpr mice spontaneously develop a severe SLE-like phenotype characterized by autoantibodies to nuclear antigens, glomerulonephritis, and skin inflammation. To assess whether JAK inhibition prevented the immunopathology, tofacitinib treatment was started in MRL/ lpr mice at 10 weeks of age, when they lacked any overt lupus manifestations ( Figure 1A) . At 18 weeks, vehicletreated MRL/lpr mice had high levels of ANAs and anti-dsDNA antibodies compared to control MRL/MpJ mice, whereas tofacitinib treatment blocked the appearance of autoantibodies ( Figure 1B) . MRL/lpr mice also developed renal disease, as manifested by glomerular hypercellularity and immune complex deposition. Tofacitinib prevented renal pathology, as judged by changes in the histopathology scores and immune complex deposition ( Figure 1C) . Renal pathology can also be assessed by measuring the levels of proteinuria (urinary albumin-to-creatinine ratio). In tofacitinib-treated MRL/lpr mice, proteinuria levels were significantly reduced as compared with the controls ( Figure  1D ). Additionally, we found a reduction in serum levels of BUN in tofacitinib-treated MRL/lpr compared with control mice, although this difference was not significant (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 39818/abstract). MRL/lpr mice typically develop an erythematous scarring rash reminiscent of lupus in humans (28, 29) . The vehicle-treated mice developed facial and dorsal skin hyperplasia, rash, and alopecia more frequently than the tofacitinib-treated mice did (Supplementary Figure 2 , available at http://onlinelibrary.wiley.com/ doi/10.1002/art.39818/abstract). Furthermore, histologic analysis showed significantly reduced hyperplasia and skin inflammatory infiltrates in tofacitinib-treated mice compared to vehicle-treated mice ( Figure 1E ). Overall, preventive treatment with tofacitinib significantly limited renal damage and skin inflammation.
A characteristic immunopathologic feature of disease in MRL/lpr mice is massive splenomegaly and lymphadenopathy caused by hyperproliferation of T cells and B cells as well as expansion of double-negative CD31CD4-CD8-T cells (30) . Therefore, we next compared splenic cell subsets in the preventive tofacitinib-treated versus vehicle-treated groups. Spleens from the tofacitinib-treated mice were reduced in size and total cell numbers when compared to those from vehicle-treated mice (Figure 2A Figure 3B ) (31) . Our data suggested that tofacitinib had the greatest effects on T cell homeostasis in the preventive model.
Because tofacitinib affects cytokines that can affect hematopoiesis including red blood cells (11), we also examined this outcome. Significant reduction in red blood cell numbers and the hemoglobin and hematocrit values were evident after 8 weeks of tofacitinib treatment (Table 1) . No changes were seen in neutrophil, monocyte, eosinophil, and basophil numbers. Overall, these results indicate that tofacitinib ameliorates the clinical features of murine lupus with expected effects on erythrocytes and lymphoid cells but not myeloid cells.
Reduction of proinflammatory cytokine levels and modulation of type I IFN responses following tofacitinib treatment in MRL/lpr mice. Overproduction of an array of cytokines is an important contributor to immunopathology in human and murine models of lupus (3). Vehicle- 
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treated MRL/lpr mice had elevated levels of proinflammatory cytokines, including TNF, IFNg, interleukin-17A (IL-17A), IL-2, and macrophage inflammatory protein 1a (CCL3), and preventive treatment with tofacitinib normalized the cytokine levels (Supplementary Figure 4 , available at http://onlinelibrary.wiley.com/doi/10.1002/ art.39818/abstract). Overproduction of IFNs is also a hallmark of lupus and can be measured by the expression of ISGs in tissues (7, 32) . The expression of multiple ISGs was significantly reduced in the splenocytes of tofacitinibtreated mice as compared to the vehicle-treated mice in the preventive trial ( Figures 3A and B) . Furthermore, increased expression of ISGs was observed in the renal tissue of MRL/lpr mice, and tofacitinib administration resulted in a significant decrease in the expression of ISGs ( Figure 3C ). Overall, these results indicate that preventive administration of tofacitinib is effective in suppressing IFNdependent and JAK/STAT-related genes and significantly Original magnification 3 63. B, Extracellular DNA release by neutrophils that were left unstimulated or were stimulated with LPS, as detected using Sytox green dye. C, Assessment of endothelium-dependent vasorelaxation in mouse aortas. Isolated aortas were exposed to phenylephrine to induce maximal contraction, followed by exposure to increasing concentrations of acetylcholine (Ach) to induce relaxation. D and E, Representative images showing the identification of mature endothelial cells (ECs), as determined by dual uptake of Hoechst 33342 (blue), acetylated low-density lipoprotein (red), and BS lectin (green) (D). Experiments were performed in triplicate; 3 photomicrographs were obtained per well. Bars 5 100 mm. Mature endothelial cells were then quantified per high-power (HP) field (E). Values in B, C, and E are the mean 6 SEM of 10 mice per group. * 5 P , 0.05; *** 5 P , 0.001; **** 5 P , 0.0001 by two-way analysis of variance in B and C and by Mann-Whitney U test in E.
limiting the synthesis of proinflammatory cytokines, all of which have been implicated in the pathogenesis of lupus.
Significantly decreased release of NETs following tofacitinib treatment. Recent evidence implicates dysregulated NET formation and clearance as a mechanism that leads to enhanced exposure of modified nuclear autoantigens, amplification of type I IFN and other proinflammatory responses, and induction of vascular damage in human and murine SLE. Indeed, we previously showed that MRL/lpr mice display enhanced spontaneous NETosis that promotes plasmacytoid dendritic cell activation, leading to increased type I IFN responses (2, 23) . As the JAK/STAT pathway is functional in neutrophils and cytokines can prime NETosis, we determined whether tofacitinib modulates NET formation in bone marrowderived neutrophils. While the total numbers of neutrophils in the peripheral blood (Table 1 ) and in the bone marrow (data not shown) were essentially unchanged with treatment, both spontaneous and LPS-induced NETosis were significantly decreased in neutrophils obtained from tofacitinib-treated mice ( Figures 4A and B) .
Improved endothelium-dependent vasorelaxation, endothelial cell differentiation, and lipoprotein profiles following tofacitinib treatment in MRL/lpr mice. We previously demonstrated that MRL/lpr mice exhibit impaired endothelium-dependent vasorelaxation, suggesting endothelial dysfunction (23) . Moreover, type I IFNs have been implicated in premature vascular damage in human and murine lupus, as well as in the induction of abnormal phenotype of endothelial progenitor cells involved in vascular repair (33, 34) . Given the effect of tofacitinib on several cytokines potentially involved in vascular dysfunction, we assessed whether the drug would modulate vascular function and repair (18, 19, 35) . Indeed, prophylactic tofacitinib treatment resulted in significant improvements in endothelium-dependent vasorelaxation ( Figure 4C ). Furthermore, the capacity of endothelial progenitor cells to differentiate into mature endothelial cells in vitro following proangiogenic stimulation was significantly increased in the tofacitinib group (Figures 4D and E) .
Recent studies in RA patients indicated that tofacitinib has beneficial effects on lipoprotein metabolism by modifying cholesterol ester catabolism and HDL function (36) . Similar to the findings in human RA, we observed that total HDL cholesterol was significantly increased in the tofacitinib-treated mice, with a more prominent effect on HDL cholesteryl ester, indicating that tofacitinib treatment restored lipoprotein homeostasis (Supplementary Figure 5 , available at http://onlinelibrary.wiley.com/doi/10. 1002/art.39818/abstract). Overall, these results indicate that JAK/STAT inhibition improves lupus vasculopathy and modulates deleterious lipoprotein profiles in murine lupus.
Limited manifestations of lupus following therapeutic treatment with tofacitinib in MRL/lpr mice. Finally, to determine whether tofacitinib could reverse established disease, drug administration was delayed until signs of active lupus (proteinuria) were evident in all of the animals (14 weeks of age), and treatment was continued for 6 weeks (therapeutic treatment arm) ( Figure 1A ). Given that with the preventive treatment, autoantibody production, proteinuria, endothelial cell differentiation, and induction of ISGs were the most significantly altered in response to tofacitinib, we focused our analysis on these parameters for the therapeutic treatment. Notably, in the tofacitinibtreated group, we observed significant reductions in antidsDNA antibody levels, whereas ANAs were also reduced but not significantly ( Figure 5A ). Proteinuria was significantly reduced ( Figure 5B), and serum levels of BUN and creatinine were reduced in the tofacitinib-treated group (Supplementary Figure 6 , available at http://onlinelibrary. wiley.com/doi/10.1002/art.39818/abstract).
Tofacitinib-treated mice displayed a significant increase in endothelial differentiation and a trend toward improvement in endothelial-dependent vasorelaxation, although in these mice, which were treated for only 6 weeks, the improvement in vasorelaxation did not reach statistical significance ( Figure 5C and Supplementary Figure 7, available at http://onlinelibrary.wiley.com/doi/10. 1002/art.39818/abstract). Importantly, as we previously observed with the preventive treatment, gene expression analysis showed a significant reduction in ISGs in the tofacitinib-treated group. In particular, type I IFN-driven ISGs (Mx-1, STAT-1, ISG-15, and IFIT-1) were the most significantly reduced ( Figure 5D ) (37, 38) . Taken together, these results indicate that tofacitinib administration results in amelioration of disease-associated features when administered to mice with established lupus features.
DISCUSSION
While treatments for SLE have improved over the last several decades, current therapies are still suboptimal, promote significant side effects, and thus far, have not been shown to consistently modify both lupus disease activity and the enhanced cardiovascular risk that is characteristic of this disease. We have now shown that the use of oral JAK inhibitors, specifically tofacitinib, a drug that preferentially targets JAK-1 and JAK-3, has pleiotropic beneficial effects in murine lupus including significant amelioration of clinical phenotype and organ damage, modulation of innate and adaptive immune dysregulation, and improvement in vascular functions and lipoprotein profiles. The observed effects of tofacitinib on innate and adaptive immune dysregulation The main effects induced by tofacitinib on adaptive immune cells were a reduction in the numbers of CD81 and double-negative T cells. This is consistent with other inflammatory models driven by cytotoxic CD81 lymphocytes, where JAK inhibition strongly suppressed these responses (16, 17, 39) . In SLE, higher numbers of cytotoxic effector CD81 T cells are associated with disease activity and may lead to autoantigen generation through perforin/ granzyme-related pathways (40) . Double-negative T cells are expanded in the peripheral blood and tissues of SLE patients as well as murine models of SLE. These cells synthesize proinflammatory cytokines and induce antibody production through promotion of B cell differentiation (41) (42) (43) (44) . Given the significant reductions in splenic double-negative T cells induced by tofacitinib and the decreases in circulating cytokine levels, it is likely that some of the beneficial effects of this drug in the lupus phenotype, including vasculopathy, are due to repression of such responses (45) .
Synthesis of type I IFNs driven by endogenous nucleic acids is considered an early event that primes the immune system for immune dysregulation and development of autoimmunity. Thus, strategies that target the type I IFN pathway are being actively investigated (46) . Considering that type I IFNs signal through the JAK/STAT pathway, tofacitinib treatment blocked the biologic responses to these cytokines, which, in our study, was reflected in significant decreases in the type I IFN signature in these mice. It is likely that inhibition of this pathway by tofacitinib led to pleiotropic effects that limited the dysregulation of the innate and adaptive immune responses, including their roles in priming neutrophils to undergo NET formation, alterations in B cell ontogeny, as well as improvements in lupus vasculopathy.
NETs have been proposed to represent an important source of immunostimulatory molecules and modified autoantigens that can trigger loss of tolerance in predisposed hosts. Furthermore, NETs are involved in the induction of type I IFN responses through activation of plasmacytoid dendritic cells. Cytokines, autoantibodies, and immune complexes can trigger enhanced NET formation and may be involved in neutrophil dysregulation in SLE (2) . As tofacitinib treatment led to decreases in all of these lupus-associated features, it is possible that this is an important mechanism by which this drug improves the clinical phenotype as well as vascular dysfunction. We previously showed that both human and murine lupus is characterized by profound impairments in endothelium-dependent vasorelaxation and an inability of the damaged vasculature to undergo proper vascular repair (47) . Importantly, tofacitinib administration led to significant improvements in these parameters. While the mechanisms leading to amelioration of the vasculopathy with tofacitinib therapy are as yet unclear, the significant modulation promoted by this drug in type I IFN responses and NET formation, both of which are considered important factors in premature endothelial damage, make it likely that these are the key downstream pathways by which this drug was effective (18, (48) (49) (50) .
Lipoprotein dysregulation is associated with the development of atherosclerosis and cardiovascular disease. This is particularly relevant in patients with chronic inflammatory diseases that carry an enhanced risk of vascular complications (51) . Previous evidence concerning the promotion of beneficial versus detrimental lipoprotein modulation by tofacitinib has been contradictory. Tofacitinib has been reported to increase HDL (36) , and recent studies indicate that this drug can restore lipoprotein homeostasis and improve cholesterol efflux capacity in RA patients (36, 52) . It has been proposed that the effects of tofacitinib on cholesterol transport result from an increase in the cholesterol ester production rate through augmented activity of the lecithin:cholesterol acyltransferase (36) . Given the changes observed in the lipoprotein profiles of tofacitinib-treated mice, particularly the reduction in the free cholesterol fraction, which has recently been shown to be proatherogenic, the lipoprotein changes induced by tofacitinib could be an additional mechanism by which JAK inhibition may be vasculoprotective in systemic autoimmunity (53) . Nevertheless, the molecular events leading to a change in the lipid balance following JAK inhibition need to be further investigated. Future studies should address the role of tofacitinib in the modulation of vascular health and its effects on the endothelium in human SLE.
Various JAK isoform-selective inhibitors are currently being developed and tested in preclinical models and early-stage clinical trials (14) . The availability of such reagents will allow us to better define the molecular events that lead to the efficacy of tofacitinib and new JAK inhibitors in SLE and SLE-associated cardiovascular disease. While the mice in this study tolerated the drug well despite a drop in red blood cell counts, presumably due to JAK-2-mediated erythropoietin inhibition (54) , in future studies, it will be important to assess the effect of JAK inhibitors on predisposition to infections and overall immune surveillance.
In summary, tofacitinib administration to lupusprone mice resulted in significant improvements in clinical phenotype, immune dysregulation, and vasculopathy characteristic of this disease. These results suggest that modulation of the JAK/STAT pathway has the potential to be beneficial in the treatment of SLE and its associated vascular damage. 158 FURUMOTO ET AL
